Cambridge Healthtech Institute's Seventh Annual
Bispecific Antibody Therapeutics
( 双特异性抗体疗法 )
2018年1月11日 - 12日
Cambridge Healthtech Institute's Bispecific Antibody Therapeutics conference explores the challenges of engineering multi-specificity to achieve more effective therapies that bind to at least two molecular targets simultaneously. These next-generation antibody formats are showing efficacy in the efforts to conquer cancer and other diseases. Case studies will highlight novel engineering approaches that address safety, stability, enhanced targeting, and manufacturability, as the conference examines current developments, and future directions for these promising molecules.
Creating Next-Generation Therapies
Examples of Development Strategies for Next-Generation Therapeutics
Nicola Beaucamp, Ph.D., Head, Process Research, Pharma Research and Early Development, Roche Innovation Center, Roche Diagnostics GmbH
Design and Evaluation of Next-Generation Biologics for Cancer Immunotherapy
Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata
Molecular Breakthrough for Enhancing Multi-Specificities
Co-Stimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART and TRIDENT Molecules
Gundo Diedrich, Ph.D., Associate Director, Antibody Engineering, MacroGenics, Inc.
From the Bench to the Clinic: Developing Next-Generation ADAPTIR Molecules
David Bienvenue, Ph.D., Senior Director, Protein Sciences, Aptevo Therapeutics
Engineering IgM CH2 Domain as a Versatile Building Block for the Construction of Various Multispecific Antibodies
Jijie Gu, Ph.D., Research Fellow and Function Head, AbbVie Bioresearch Center
Engineering Improved Properties
Identification and Quantitation of DuoBody Bispecific IgG1 Using Mass Spectrometry and Automated Data Processing and Analysis Workflow
Ewald Van den Bremer, Ph.D., Senior Scientist, Genmab A/S
An IgM-based Bispecific Platform for Enhanced T-Cell and Complement Dependent Cytotoxicity on Low Antigen Expressing Cells
Ramesh Baliga, Ph.D., Vice President, Discovery Biology, IGM Biosciences, Inc.
A Novel Trifunctional Antibody Combining PD-1/PD-L1 Blockade and Targeting of a Tumor-Specific Carbohydrate Antigen
Christoph Goletz, Associate Director, Immunomodulation, Glycotope GmbH